FDA approves AstraZeneca's Etcamah combo for advanced breast cancer

The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer. The approval is based on findings from the SERENA-6 Phase III trial. The combo is approved for adults with locally advanced or metastatic breast cancer. Credit: NMK-Studio / Shutterstock.com. The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer. This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. LOA and PTSR Model -…

Source: Pharmaceutical Technology